Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial
M. Tabberer (Middlesex, United Kingdom), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Middlesex, United Kingdom), G. Criner (Philadelphia, United States of America), P. Lange (Copenhagen, Denmark), M. Han (Ann Arbor, United States of America), F. Martinez (New York, United States of America), D. Lipson (King of Prussia, United States of America)
Source: International Congress 2018 – Clinical trials in COPD: new results
Session: Clinical trials in COPD: new results
Session type: Oral Presentation
Number: 1658
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Tabberer (Middlesex, United Kingdom), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Middlesex, United Kingdom), G. Criner (Philadelphia, United States of America), P. Lange (Copenhagen, Denmark), M. Han (Ann Arbor, United States of America), F. Martinez (New York, United States of America), D. Lipson (King of Prussia, United States of America). Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial. 1658
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: